Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Cancer Vaccines01:30

Cancer Vaccines

946
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
946
Vaccinations01:51

Vaccinations

51.2K
Overview
51.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Computationally Aided Design of Ionizable Cholesteryl Lipids for Lipid Nanoparticles to Modulate Hepatic mRNA Accumulation.

Journal of the American Chemical Society·2025
Same author

33 Unresolved Questions in Nanoscience and Nanotechnology.

ACS nano·2025
Same author

Modulating tumor collagen fiber alignment for enhanced lung cancer immunotherapy via inhaled RNA.

Nature communications·2025
Same author

Budesonide-incorporated inhalable lipid nanoparticles for antiTSLP nanobody mRNA delivery to treat steroid-resistant asthma.

Nature communications·2025
Same author

Prevent and Reverse Metabolic Dysfunction-Associated Steatohepatitis and Hepatic Fibrosis via mRNA-Mediated Liver-Specific Antibody Therapy.

ACS nano·2024
Same author

Optimized inhaled LNP formulation for enhanced treatment of idiopathic pulmonary fibrosis via mRNA-mediated antibody therapy.

Nature communications·2024

Related Experiment Video

Updated: Jan 13, 2026

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
10:04

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

1.4K

mRNA-Based Vaccination Drives in Vivo Dendritic Cell Reprogramming and Selective Cytotoxic T Lymphocyte Modulation

Chenshuang Zhang1, William Stewart2, Yilong Teng1

  • 1National Key Laboratory of Innovative Immunotherapy, Shanghai Frontiers Science Center of Drug Target Identification and Delivery, School of Pharmaceutical Sciences, Shanghai Jiao Tong University, Shanghai 200240, China.

ACS Nano
|October 28, 2025
PubMed
Summary
This summary is machine-generated.

This study introduces VISIT, a novel vaccine strategy that reprograms dendritic cells in vivo to enhance cancer immunotherapy. VISIT effectively boosts antigen-specific T cell responses, leading to tumor rejection and long-term immunity.

Keywords:
cytotoxic T lymphocytesdendritic cell reprogramminglipid nanoparticlemRNAtumor vaccine

More Related Videos

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy
08:40

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

18.6K
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.9K

Related Experiment Videos

Last Updated: Jan 13, 2026

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
10:04

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

1.4K
Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy
08:40

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

18.6K
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.9K

Area of Science:

  • Immunology
  • Cancer Biology
  • Biotechnology

Background:

  • Engineering T cells for cancer immunotherapy faces challenges in tumor recognition and T cell insufficiency.
  • Current strategies require precise control over T cell activation and expansion in vivo.

Purpose of the Study:

  • To present a streamlined strategy, VISIT (vaccine-initiated selective T cell modulation), for spatiotemporal modulation of cytotoxic T lymphocytes (CTLs).
  • To enable in vivo dendritic cell (DC) reprogramming for enhanced cancer immunotherapy.

Main Methods:

  • Utilized optimized lipid nanoparticles to deliver mRNA to splenic DCs, co-delivering tumor antigens and IL-15/IL-15Rα complex.
  • Focused on in vivo DC reprogramming to promote antigen-specific CTL activation and expansion.

Main Results:

  • Prophylactic vaccination led to complete tumor rejection and established long-term immunological memory.
  • Systemic vaccination in established tumor models inhibited tumor growth and maximized CTL responses.
  • Combination therapy with immune checkpoint inhibitors showed synergistic effects, extending survival in melanoma models.

Conclusions:

  • The VISIT platform offers a novel in vivo DC reprogramming approach for cancer immunotherapy.
  • VISIT enables precise spatiotemporal modulation of DC-T cell interactions for personalized cancer treatments.